At a glance
ClinicalIndex Comparison RecordN/ACompleted· 236,507 enrolled
Drug / intervention
Pioglitazonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes Mellitus
In Brief
An observational study evaluating Pioglitazone for Diabetes Mellitus, Type 2, Cancer. Completed, enrolled 236,507 participants.
Detailed Summary
The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2, Cancer
Countries--
Collaborators--
Timeline
N/ACompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 1997
Primary CompletionMay 2015
First PostedNov 2016
TodayJul 2026
First PostedNov 8, 2016
Enrollment StartJan 1, 1997
Primary CompletionMay 29, 2015
TodayJul 2, 2026
Enrollment to primary: 18.4 yearsPosted 9.7 years ago
Interventions
Pioglitazonedrug
Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.